Psoriatic Arthritis & Ankylosing Spondylitis

These spondyloarthropathies benefit from:

• IL-17 inhibitors (secukinumab, ixekizumab)
• IL-23 inhibitors (guselkumab, risankizumab)
• TNF blockade remains foundational for axial disease